> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hold on Tryp Therapeutics Eating Disorder Study
- URL: https://www.fdaweb.com/hold-on-tryp-therapeutics-eating-disorder-study/
- Published: 2021-10-22T12:00:00.000Z
- Updated: 2026-09-14T17:19:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150425

FDA has placed a clinical hold against Tryp Therapeutics and a Phase 2a study evaluating its psilocybin for eating disorders (binge eating disorder and hypothalamic obesity). The company says the agency notification did not provide a reason for the clinical hold and advised that additional details on any deficiencies will be provided within 30 days.

The hold will not impact plans to file a separate IND within the next 10 days for its Phase 2a study in fibromyalgia through a collaboration with the University of Michigan, Tryp says. “Tryp also continues to advance both an academic collaboration for a Phase 2a clinical trial in phantom limb pain (for which an IND has already been authorized by the FDA) as well as an academic collaboration for a Phase 2a clinical trial in complex regional pain syndrome,” it says.